Abcam, ab238996, Anti-Proteasome Activator Subunit 4/PSME4 antibody [EPR13577(B)] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal Proteasome Activator Subunit 4/PSME4 antibody. Carrier free. Suitable for WB, IHC-P and reacts with Mouse, Rat, Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR13577(B),
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat, Human,
Applications:IHC-P, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:The mouse and rat recommendation is based on the WB results. We do not guarantee IHC-P for mouse and rat.

Product details:
ab238996 is the carrier-free version of
ab181203
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Proteasome Activator Subunit 4 (PSME4) also known as PA200 is an important component in regulating protein degradation. It belongs to the family of proteasome activator subunits and has a molecular mass of approximately 230 kDa. PSME4 is mainly expressed in the nucleus of cells and modulates proteasome activity by binding to the proteasome core particle. Through facilitating protein breakdown PSME4 significantly influences various cellular processes including the elimination of oxidatively damaged proteins.
Biological function summary
PSME4 functions as part of a complex that enhances proteasome-mediated protein degradation. This complex formation improves the efficiency of protein processing by recruiting specific substrates for degradation. PSME4 is involved in DNA repair processes and plays a role in spermatogenesis contributing to proper cell cycle progression and genomic stability. The protein's activity in these biological functions demonstrates its importance in maintaining cellular homeostasis.
Pathways
PSME4 is intricately involved in the ubiquitin-proteasome pathway and the DNA damage response pathway which are essential for maintaining protein quality control and genomic integrity. PSME4 interacts with other proteins such as RAD23B facilitating the repair of damaged DNA. By integrating into these pathways PSME4 ensures the proper execution of critical cellular processes and responds to stress-related signals.
Alterations in PSME4 expression or function have connections to cancer progression and neurodegenerative diseases. In cancer PSME4 may influence tumor growth and resistance to therapy through its role in DNA repair and protein turnover. Additionally in neurodegenerative conditions like Alzheimer's disease PSME4-associated proteasome dysfunction contributes to the accumulation of toxic protein aggregates. Understanding PSME4 interactions with proteins like p53 in cancer or tau in neurodegeneration offers insights into potential therapeutic targets.